Progress report on the first sub-Saharan trial of newer versus older ... - 7thSpace Interactive (press release)
Progress report on the first sub-Saharan trial of newer versus older .
Novartis profit falls on generic competition and charges - PMLiVE
Novartis profit falls on generic competition and chargesPMLiVERevenues fell 2 per cent to $13.
Novartis: A Sleeper Or A Headache? - Seeking Alpha
Novartis: A Sleeper Or A Headache?Seeking AlphaThis last quarter, Novartis missed the street estimates mainly because of looming patent expiration of some of their best-selling prescription drugs, most notably Diovan (valsartan).
Novartis Pressures Generics Makers Over Exforge ANDA - Law360 (subscription)
Novartis Pressures Generics Makers Over Exforge ANDALaw360 (subscription).
Novartis expands in generics with $1.53bn Fougera buy - PMLiVE